Wix.com Ltd (WIX) is slated to report fourth-quarter 2023 results on Feb 21.The company expects fourth-quarter revenues to be between $400 million and $405 million, suggesting 13-14% growth from the prior-year figure. The Zacks Consensus Estimate is pegged at $402.6 million, indicating an increase of 13.4% from a year ago.The Zacks Consensus Estimate for earnings is pegged at 98 cents per share. The company reported earnings of 61 cents in the year-ago quarter.WIX’s earnings beat the Zacks Consensus Estimat ...

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor R ...

Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and provides additional flexibility on projected runway through positive cash-flow around end of 2026 Codexis management to host conference call today at 4:30 pm ET REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into ...

BEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the creation of an engineered high-performance transposase enzyme designed to drive superior performance in sequencing applications. The co-development of this new transposase enzyme – called TnX transposase – builds upon a multi-year partnership between the two companies, leveraging ...

These slides contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will, ...

Codexis, Inc. (NASDAQ:CDXS) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Carrie McKim - Director of IR Stephen Dilly - President and CEO Kevin Norrett - Chief Operating Officer Sri Ryali - CFO Conference Call Participants Brandon Couillard - Jefferies Dan Urrea - Stifel Matt Hewitt - Craig-Hallum Chad Wiatrowski - TD Cowen Operator Welcome to the Codexis Third Quarter 2023 Earnings Conference Call. [Operator Instructions]. Please note this even is being recorded. And now ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) _____________________________________________ Delaware 71-0872999 (State or other jurisdiction of incorp ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------|----------------------------------|-------|----------------|-------|------------------------------------------|-------|-----------------------------------|--------------------------------------------| | Three Months Ended June 30, 2023 \nBalance as of April 1, 2023 | Common Stock \nShares \n66,696 | $ | \nAmount \n6 | $ | Additional Paid-in \nCapital \n569,917 | $ | ...

Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources. | --- | --- | --- | --- | --- | --- ...

16 For example, a product candidate is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical developmen ...